Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in what would be the latest big deal in the red-hot biotechnology sector.

MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”).

SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.

National Health Commission of the PRC recently convened a meeting in Beijing to outline ten practical initiatives for public service by 2026.

Adaptive Biotechnologies said last week that its new subsidiary Digital Biotechnologies has held an initial closing of its Series A preferred stock financing and expects to raise up to $15 million in the round.

Mdxhealth and the University of Oxford will test whether the firm's Genomic Prostate Score (GPS) assay can predict disease progression and treatment outcomes in prostate cancer patients, the company said Tuesday.

As indicated by the release of the China Cardiovascular Health and Disease Report 2024, the current number of cardiovascular patients is 330 million and is still on the rise.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that as of the date of this press release, its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased US$811,721.28 of the Company’s ADSs from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. Mr. Han’s purchase of the Company’s ADSs indicates his confidence in the Company’s business and prospect.

Corewell Health and Quest Diagnostics (NYSE: DGX) today announced the completion of the previously announced transaction to establish a laboratory services joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.